GlassScriptPhysician profile
Grace Song
NPI 1255891529
$694.29
in general payments reported to CMS, 2019-2025
15 companies · $18.53 in 2025
The $18.53 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $270 · 2023: $377 · 2024: $29.32 · 2025: $18.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $424.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $125.00 | 2022 | |
| Novo Nordisk INC | $121.38 | 2022-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $69.55 | 2022-2023 | Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $62.18 | 2023-2025 | Airsupra, Farxiga |
| Pfizer INC. | $54.00 | 2022-2023 | |
| Lilly USA, LLC | $52.10 | 2022-2023 | Mounjaro |
| Sanofi Pasteur INC. | $39.53 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.50 | 2023 | |
| Merck Sharp & Dohme LLC | $30.06 | 2023 | Gardasil 9, Vaxneuvance, Vaxelis |
| Teva Pharmaceuticals USA, INC. | $27.99 | 2023 | Ajovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.61 | 2023 | Jardiance |
| Dexcom, INC. | $17.76 | 2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $17.13 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $13.93 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.